Civil Litigation,
Intellectual Property
Nov. 19, 2019
The fate of patent invalidity challenges post-Arthrex: much ado about nothing?
Following the Federal Circuit decision in Arthrex, Inc. v. Smith & Nephew, Inc., et al., significant attention has been paid to its potential impact on appeals of inter partes review decisions from the Patent Trial & Appeals Board.
Erin Gaddes
Maynard Cooper & Gale, LLPErin is a patent agent in the Firm's Huntsville office and is a member of Maynard Cooper's Intellectual Property Practice Group. She assists attorneys in the IP Group to evaluate patentability, provide scientific guidance, and prepare and prosecute patent applications.
Following the U.S. Court of Appeals for the Federal Circuit's decision in Arthrex, Inc. v. Smith & Nephew, Inc., et al. on Oct. 31, significant attention has been paid to its potential impact on appeals of inter partes review decisions from the Patent Trial & Appeals Board. Arthrex, Inc. v. Smith & Nephew, Inc. et al., 18-2140 (Fed. Cir. Oct. 31, 2019) IPRs became a very popular means of challenging t...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In